Myricx Bio
Business Services · United Kingdom · 1-10 Employees
View Company Info for Free
Overview
Headquarters
Gridiron Building 1 Pancras King's Cross...Website
www.myricxbio.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Myricx Bio
Myricx Bio (Myricx) is a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer. NMT is an enzyme that adds a specific lipid modification to a number of protein targets key to cancer cell survival. The company is advancing a pipeline of ADCs based on the company's novel NMT inhibitor (NMTi) payload chemistry platform to address serious unmet needs in oncology. The company's proprietary ADCs have demonstrated compelling preclinical efficacy and safety across multiple solid tumour associated antigens and specific cancer cell types.Explore more
Myricx Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Myricx Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Myricx Bio had a recent Job posting/layoffs
Earning: See what the market has to say on Myricx Bio recently announced quarterly report
Myricx Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Myricx Bio has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at Myricx Bio
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Myricx Bio has new funding data
Product Launch: Get notified when Myricx Bio launches new products
Check out if Myricx Bio is spiking on competitors!
Recommended Actions
Find VP level buyers at Myricx Bio
Find 2 more new buyers
Compare Similar Companies to Myricx Bio
Compare insights from companies similar to Myricx Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Myricx Bio is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Myricx Bio is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Myricx Bio.
Myricx Bio financials insights
Gather financial insights about Myricx Bio, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Angel/Seed
$5.9M
Angel/Seed
$5.9M
2024
Series A
$114M
Myricx Bio Tech Stack
A closer look at the technologies used by Myricx Bio
Most Recent Scoops
Person-Based
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
New Hire
Executive Move
Executive Moves, New Hire, Board of Directors
Lateral Move
Executive Move
Executive Moves, Lateral Move
New Hire
Executive Move
Executive Moves, New Hire
Myricx Bio News & Media
Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform
LONDON, July 06, 2026 (GLOBE NEWSWIRE) -- Myricx Bio, a UK-headquartered biotech company focusing on the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs), today announced that it has reached agreement to be acquired by Novartis for up to $1.5 billion including $1.1 billion cash upfront plus potential milestone payments.Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients
Basel, July 6, 2026 - Novartis today announced that it has entered into an agreement to acquire Myricx Bio (“Myricx”), a privately held UK-based biotechnology company developing a new class of antibody-drug conjugates (ADCs), using N-myristoyltransferase inhibitor (NMTi) payloads.ADC Innovator Myricx Bio Appoints Boston-based Mohit Rawat as CEO and Expands Team in US and UK
LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a private biotech company focusing on the discovery and development of a novel class of payloads for antibody-drug conjugates (ADCs), is scaling ahead of entering the clinic and is pleased to announce the appointment of Boston-based Mohit Rawat as its Chief Executive Officer (CEO) and member of the Board of Directors.Myricx Bio Announces Expansion of its Leadership Team to Advance NMTi-ADCs into Clinical Development
LONDON, April 08, 2025 (GLOBE NEWSWIRE) -- Myricx Bio (‘Myricx’), a UK-based biotech company focusing on the discovery and development of a completely novel class of payloads for antibody-drug conjugates (ADCs), is pleased to announce team expansion, with the appointment of Steen Lisby, M.D., D.MSc. as CMO and Jesper Valbjørn, M.Sc. as SVP CMC.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Myricx Bio
Sign Up For FreeTo access detailed company insights
Myricx Bio (Myricx) is a UK biotech company focused on the discovery and development of a completely novel class of selective cytotoxic payloads for antibody drug conjugates (ADCs), based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer. NMT is an enzyme that adds a specific lipid modification to a number of protein target... Read More
